Design Therapeutics (DSGN) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 14, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Sep 30, 2026: 1 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about DSGN filings

Are insiders buying or selling Design Therapeutics Inc (DSGN) stock?

Neither. Design Therapeutics Inc (DSGN) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded DSGN recently?

None. No member of Congress disclosed a DSGN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this DSGN smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

SSState StreetQ3 2026 13FAdded$10.4M

13F: filed up to 45 days late.

Smart money on DSGN

Lean long1 source:
- Funds

Top traders
No tracked positions at the last update
Insiders
No recent insider filings found
Congress
No recent politician filings found
Funds
- State Street, added +$10.4M, holdings at Sep 30
Lean long · thin1 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Influencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about DSGN filings

Are insiders buying or selling Design Therapeutics Inc (DSGN) stock?

Neither. Design Therapeutics Inc (DSGN) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded DSGN recently?

None. No member of Congress disclosed a DSGN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this DSGN smart-money data?

Funds

What funds are doing

1 move · 6 mo

Buys/Adds$10.4M

Buys/Adds (1)

SS
State Street
Q3 2026 13F
$10.4M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 4, 2026

Earnings came in 7.6% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 4, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.32+7.58% beat

-$0.35 expected

Revenue

$0.00

SEC filing · No operating revenue

EPS: Yahoo Finance

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 4, 2026	-$0.32est. -$0.35	+7.58%beat	$0.00SEC filing	No year-ago quarter
Jun 30, 2026Reported Aug 3, 2026	-$0.32est. -$0.34	+7.06%beat	$0.00SEC filing	No year-ago quarter
Mar 31, 2026Reported Apr 28, 2026	-$0.29est. -$0.33	+13.17%beat	$0.00SEC filing	No year-ago quarter
Dec 31, 2025Reported Mar 9, 2026	-$0.27est. -$0.35	+23.73%beat	$0.00Yahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 5, 2025	-$0.30est. -$0.34	+11.76%beat	$0.00 · 9MSEC filing	No year-ago quarter
Jun 30, 2025Reported Aug 7, 2025	-$0.34est. -$0.32	-6.25%miss	$0.00 · 6MSEC filing	No year-ago quarter
Mar 31, 2025Reported May 7, 2025	-$0.31est. -$0.28	-10.71%miss	$0.00SEC filing	No year-ago quarter
Dec 31, 2024Reported Mar 10, 2025	-$0.24est. -$0.27	+10.01%beat	$0.00 · FYSEC filing	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $10.61
High: $10.88
Low: $10.27
Prev close: $10.77
52-wk high: $17.25
52-wk low: $7.24
Mkt cap: $689.7M
ROE: -36.9%
Beta: 1.75
P/S: 29402.8x
P/B: 3.4x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $690M

Valuation

P/S29402.82
P/B3.37

Quality

Operating margin0.0%
ROE-36.9%
ROA-23.9%

Growth

Beta1.75

Technicals

Price structure

This stock's price action is mixed.

Trend

Mixed

55 / 100

RSI 14

54balanced

20D volatility

61%annualized

52-week range

$10.58

$7.24$17.25

20D support

$9.62recent floor

20D resistance

$11.50recent ceiling

Returns

5D +9.4%20D +1.0%60D -33.6%

Price vs moving averages

SMA20 +0.2%SMA50 -10.2%SMA200 -13.2%

Volume pace

0.60xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 4, 2026

-$0.32est. -$0.35

+7.58%

$0.00SEC filing

No year-ago quarter

Jun 30, 2026Aug 3, 2026

-$0.32est. -$0.34

+7.06%

$0.00SEC filing

No year-ago quarter

Mar 31, 2026Apr 28, 2026

-$0.29est. -$0.33

+13.17%

$0.00SEC filing

No year-ago quarter

Dec 31, 2025Mar 9, 2026

-$0.27est. -$0.35

+23.73%

$0.00Yahoo Finance

No year-ago quarter

Sep 30, 2025Nov 5, 2025

-$0.30est. -$0.34

+11.76%

$0.00 · 9MSEC filing

No year-ago quarter

Jun 30, 2025Aug 7, 2025

-$0.34est. -$0.32

-6.25%

$0.00 · 6MSEC filing

No year-ago quarter

Mar 31, 2025May 7, 2025

-$0.31est. -$0.28

-10.71%

$0.00SEC filing

No year-ago quarter

Dec 31, 2024Mar 10, 2025

-$0.24est. -$0.27

+10.01%

$0.00 · FYSEC filing

No year-ago quarter

Design Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about DSGN filings

Smart money on DSGN

Questions about DSGN filings

What funds are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 7.6% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Design Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about DSGN filings

Smart money on DSGN

Questions about DSGN filings

What funds are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 7.6% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Design Therapeutics Inc

Overview

Questions about DSGN filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Design Therapeutics Inc

Overview

Questions about DSGN filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.